
1. General Information
WEGOVY FlexTouch 2.4 mg Injection contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used along with a reduced-calorie diet and increased physical activity for long-term weight management in appropriate patients. It is also approved for reducing the risk of major cardiovascular events in certain adults with established cardiovascular disease and obesity or overweight.
The 2.4 mg dose is generally used as a maintenance dose after gradual dose escalation, helping improve tolerability.
2. Product Information
- Brand: WEGOVY
- Active Ingredient: Semaglutide
- Strength: 2.4 mg
- Dosage Form: Solution for injection
- Route: Subcutaneous injection
- Device: WEGOVY FlexTouch prefilled pen
- Frequency: Generally once weekly
- Manufacturer: Novo Nordisk
- Drug Class: GLP-1 receptor agonist
- Storage: Follow the product packaging and official prescribing information for exact storage requirements.
The WEGOVY FlexTouch 2.4 mg pen contains four fixed 2.4 mg doses, with one dose intended to be administered weekly.
3. Uses of WEGOVY 2.4 mg Injection
WEGOVY injection may be prescribed, together with diet and increased physical activity, for:
- Long-term weight management in adults with obesity.
- Weight management in adults with overweight who have at least one weight-related medical condition.
- Weight management in appropriate pediatric patients aged 12 years and older with obesity.
- Reduction of major cardiovascular events such as cardiovascular death, non-fatal heart attack, or non-fatal stroke in certain adults with established cardiovascular disease and obesity or overweight.
4. Benefits of This Medicine
When prescribed appropriately, WEGOVY may:
- Help reduce appetite and calorie intake.
- Support clinically meaningful weight loss when combined with diet and physical activity.
- Help patients maintain weight reduction over the long term.
- Provide cardiovascular risk reduction in certain eligible adults with established cardiovascular disease and obesity or overweight.
Individual results vary, and WEGOVY should be used under medical supervision.
5. Side Effects of WEGOVY 2.4 mg
WEGOVY can cause gastrointestinal and other adverse effects. Important potentially serious reactions include:
- Pancreatitis
- Gallbladder disease, including gallstones
- Severe gastrointestinal reactions
- Dehydration that may contribute to kidney problems
- Hypoglycemia, particularly when used with insulin or certain diabetes medicines
- Serious allergic reactions
- Possible thyroid C-cell tumors; the human risk is not known
WEGOVY should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or by people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
6. Common Side Effects
Common adverse reactions reported with WEGOVY include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Dyspepsia
- Dizziness
- Abdominal distension
- Belching
- Flatulence
- Gastroesophageal reflux disease
- Hair loss
The frequency and severity of side effects can vary between individuals.
7. How to Use WEGOVY FlexTouch 2.4 mg
WEGOVY injection is generally administered once weekly, on the same day each week, with or without food. It is injected subcutaneously into the abdomen, thigh, or upper arm.
The 2.4 mg dose is normally reached through a gradual dose-escalation schedule rather than being used as the starting dose. A healthcare professional should determine the appropriate dosing schedule.
For the FlexTouch pen:
- Wash your hands and check the pen.
- Use a new compatible disposable needle.
- Follow the manufacturer's instructions for attaching and preparing the needle.
- Inject the prescribed dose subcutaneously.
- Remove and safely dispose of the used needle.
- Never share the pen with another person, even if the needle has been changed.
Patients should receive appropriate training before using the FlexTouch pen themselves.
8. How WEGOVY Works
Semaglutide works similarly to the naturally occurring hormone GLP-1. It acts on GLP-1 receptors involved in appetite regulation and helps reduce appetite and calorie intake. This can support weight loss when combined with a reduced-calorie diet and physical activity.
WEGOVY also slows gastric emptying, which can affect the absorption of some oral medicines.
9. Safety Advice
- Use WEGOVY only when prescribed by a qualified healthcare professional.
- Do not use it if you or a family member has had medullary thyroid carcinoma (MTC) or if you have MEN 2.
- Tell your doctor about previous pancreas, kidney, gallbladder, or diabetic eye problems.
- Inform your healthcare provider about all medicines, supplements, and diabetes treatments you use.
- Do not combine WEGOVY with another semaglutide-containing product or another GLP-1 receptor agonist unless specifically directed by your healthcare professional.
- Seek immediate medical advice for persistent severe abdominal pain, especially if it radiates to the back.
- Pregnancy requires special consideration; for weight-management/cardiovascular indications, the FDA labeling advises discontinuing WEGOVY when pregnancy is recognized and stopping it at least 2 months before a planned pregnancy.
- Do not share the FlexTouch pen.
- Keep the medicine stored according to the official product instructions and protect it from inappropriate storage conditions.
10. FAQs
Q1. What is the active ingredient in WEGOVY 2.4 mg?
The active ingredient is semaglutide, a GLP-1 receptor agonist.
Q2. How often is WEGOVY 2.4 mg administered?
It is generally administered once weekly.
Q3. Is 2.4 mg the starting dose?
No. WEGOVY injection is normally started at a lower dose and gradually increased every four weeks to reduce gastrointestinal adverse reactions.
Q4. Can WEGOVY be used with food?
Yes. The injection can generally be administered at any time of day, with or without meals.
Q5. Where is WEGOVY injected?
It is administered subcutaneously in the abdomen, thigh, or upper arm.
Q6. Can I share my WEGOVY FlexTouch pen?
No. The pen must not be shared, even if the needle is changed.
Q7. Can WEGOVY be used during pregnancy?
WEGOVY may harm an unborn baby. Patients who are pregnant or planning pregnancy should discuss treatment with their healthcare professional.
Q8. Can WEGOVY be taken with other GLP-1 medicines?
WEGOVY should not be combined with another semaglutide-containing product or another GLP-1 receptor agonist unless specifically directed by a healthcare professional.
Q9. What should I do if I miss a dose?
According to current FDA labeling, if the next scheduled dose is more than two days away, the missed injection may be administered as soon as possible. If the next dose is less than two days away, the missed dose should generally be skipped and the regular schedule resumed.
11. Substitute for WEGOVY 2.4 mg
There is no universal one-to-one substitute for WEGOVY 2.4 mg. Alternatives depend on the patient's indication, medical history, treatment goals, availability, and prescribing requirements.
Medicines containing other GLP-1 or related active ingredients may be considered by a healthcare professional, but they should not be substituted or dose-matched independently.
Examples of medicines that may be considered for obesity management in appropriate patients include other prescription anti-obesity treatments or GLP-1-based therapies. The choice should be made by a qualified healthcare professional.
12. SEO Keywords
Primary Keywords:
- WEGOVY FlexTouch 2.4 mg Injection
- WEGOVY 2.4 mg Injection
- Semaglutide 2.4 mg Injection
- WEGOVY 2.4 mg Pen
- WEGOVY FlexTouch Pen
- Semaglutide Injection exporter
- WEGOVY medicine exporter from India
Long-Tail B2B Keywords:
- WEGOVY FlexTouch 2.4 mg Injection exporter from India
- WEGOVY 2.4 mg Injection pharmaceutical exporter in Nagpur
- Genuine WEGOVY 2.4 mg Injection supplier from India
- Semaglutide 2.4 mg Injection exporter from Nagpur India
- WEGOVY FlexTouch 2.4 mg pharmaceutical supplier India
- WEGOVY 2.4 mg Injection international pharmaceutical exporter
- WEGOVY FlexTouch 2.4 mg wholesale pharmaceutical supplier
- WEGOVY 2.4 mg Injection supplier for international markets
- Semaglutide 2.4 mg medicine exporter India to USA
- WEGOVY 2.4 mg exporter from India to UK
- WEGOVY FlexTouch supplier from India to Australia
- WEGOVY 2.4 mg pharmaceutical exporter to Singapore
- Semaglutide Injection exporter from India to Canada
- WEGOVY FlexTouch exporter from India to South Korea
- WEGOVY 2.4 mg medicine exporter from India to UAE
- Phoenix Exim WEGOVY 2.4 mg pharmaceutical exporter
- WEGOVY FlexTouch 2.4 mg international medicine supplier
- Semaglutide injection pharmaceutical supplier from Nagpur India
- WEGOVY 2.4 mg prescription medicine exporter India
- WEGOVY FlexTouch 2.4 mg global pharmaceutical supply
Company/Location Keywords:
- Phoenix Exim medicine exporter Nagpur India
- Phoenix Exim pharmaceutical exporter India
- Nagpur pharmaceutical exporter
- Indian medicine exporter to USA UK Australia
- Indian pharmaceutical exporter to Singapore Canada Korea UAE
- trusted pharmaceutical exporter from India
- international medicine supplier from India
- pharmaceutical export company in Nagpur
Keywords







